Cathepsin k: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
 
(99 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<StructureSection load='1atk' size='350' side='right' caption='Human Cathepsin K' scene='72/727885/Cathepsin_k_helix_sheet/1' pspeed='8'>
==Introduction==
'''Cathepsin K''' is a member of a large family of lysosomal cysteine proteases, which have been under extensive study over the past decade <ref name="kaf"/><ref name="lut"/><ref name="turk"/>. Cathepsin enzymes were originally considered general proteases found in the lysosomes of all cell types. However, recent studies have found the expression of Cathepsin K in specific tissue cells <ref name="turk"/>.
Cathepsin K is the most abundant cysteine protease produced by osteoclasts, the multinuclear cells responsible for bone resorption <ref name="stoch">doi:10.1038/sj.clpt.6100450</ref><ref name="vaan">doi:10.1016/j.addr.2004.12.018</ref>. This enzyme is also specifically expressed in chondrocytes and is capable of the cleavage of type II collagen, the component of cartilage that provides tensile strength <ref name="kaf"/>. Cathepsin K is has additionally been identified in macrophages and tumor cells and appears capable of the degradation of both apolipoproteins and elastin <ref name="turk"/><ref name="little">PMID:9393764</ref>.
==Structure==
==Structure==
<StructureSection load='1 ATK' caption='Cathepsin K and Inhibitor E-64 Complex' scene=''>
 
This is a default text for your page '''Cathepsin k'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
The <scene name='72/727885/Cathepsin_k_active_site/5'>active site</scene> of cathepsin K consists of three residues: CYS25, HIS162, and ASN182 <ref name="zao">PMID:9033588</ref>.The cleft containing the active site is flanked by two <scene name='72/727885/Cathepsin_k_globules/1'>globular domains</scene> <ref name="zao"/><ref name="lut">DOI:doi:10.1096/fj.06-7924com</ref>. Protease activity is induced by the entrance of the substrate into the active site cleft <ref name="lut"/><ref name="chap">PMID:9074757</ref>. Cathepsin K is called a cysteine protease because the cysteine residue functions as the nucleophile <ref name="chap"/>. The cysteine residue becomes deprotonated, yielding a negavitely charged <scene name='72/727885/Thiolate_anion/3'>thiolate anion</scene>, which attacks the substrate peptide bond <ref name="chap"/>. Proper function of CYS25 requires the formation of an ion pair with the neighboring basic histidine residue <ref name="chap"/>.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
 
<scene name='72/727885/Cathepsin_k_helix_sheet/1'>Cathepsin K</scene> is initially synthesized in its inactive form, pre-procathepsin k, a 37-kDa protein made up of a single peptide chain 329 amino acids in length <ref name="mcq">PMID: 9153258</ref><ref name="boss">PMID: 8647860</ref>. The pre-procathepsin k sequence has three distinct features: a signal peptide, consisting of the first 15 amino acids at the N-terminus; a propeptide, comprising amino acids 16-114; and the main chain, which makes up the final 215 amino acids ending at the C-Terminus <ref name="uniprot">PMID: 25348405</ref><ref name="protparam">PMID: 22661580</ref>. When the enzyme is activated, the signal peptide and propeptide portions are cleaved to produce the mature cathepsin K protein weighing 27-kDa <ref name="mcq"/><ref name="boss"/>. Cathepsin K is active in acidic conditions, within a pH range of 4-6 <ref name="garn"/>.
 
The signal peptide sequence consists of hydrophobic amino acids, with the exception of one serine residue <ref name="protparam"/>. The propeptide feature contains residues of all 20 standard amino acids, excluding only cysteine and phenylalanine, with the majority comprising leucine (12.1%) and glutamate (11.1%) <ref name="protparam"/>. The activated enzyme, lacking the signal peptide and propeptide sequences, is approximately 54% hydrophillic and 46% hydrophobic, containing 19 negatively charged residues and 26 positively charged residues <ref name="protparam"/>. This net positive charge may contribute to the stability of cathepsin K at low pH <ref name="shaw">PMID:11369859</ref>.


== Function ==
== Function ==
Cathepsin K can cleave type I and type II collagen, major components of bone and cartilage matrices, and are highly expressed in osteoclasts and chondroclasts <ref name="hou">PMID:11733367</ref><ref name="kaf">pmid:9560298</ref><ref name="diaz"/>. This enzyme is unique among other cysteine proteases in that it can cleave collagen at multiple sites and in its triple helix <ref name="garn">PMID: 9822715</ref><ref name="turk">doi:10.1016/j.bbapap.2011.10.002</ref>. With facilitation by the protein chondroitin sulfate, cathepsin K forms a complex with other cathepsin K proteins to unravel and cleave the collagen triple helix <ref name="turk"/>.
Cathepsin K is also capable of degrading apolipoproteins, which reside in macrophages and facilitate the efflux of cholesterol from these cells <ref name="lind"/>. The degradation of apolipoproteins has shown to increase the cholesterol content in macrophages, which is an initial step in arterial plaque formation <ref name="lind">PMID:14651973</ref>.
Cathepsin K seems to contribute to the inflammatory response <ref name="asa">doi: 10.1126/science.1150110</ref><ref name="hou"/>. Cathepsin K is expressed by inflammatory cells in response to detected pathogens, possibly in order to cleave pathogenic proteins <ref name="diaz">pmid:11055584</ref>.


== Disease ==
== Disease ==
Deficiencies in Cathepsin K have been shown to cause pycnodysostosis, characterized by reduced bone resorption, increased bone density, and short stature <ref name="gelb">PMID:8703060</ref>. HIgh activity of cathepsin K has been associated with diseases involving excessive bone and cartilage degeneration, including osteoporosis and rheumatoid arthritis <ref name="gelb"/><ref name="hou"/>.
Cathepsin K may also take part in atherosclerosis, as high activity of cathepsin K has beed discovered in atherosclerotic lesions <ref name="lut"/>. Cathepsin K activity can promote the accumulation of cholesterol in macrophages via destruction of apolipoproteins <ref name="lind"/>. As macrophages become loaded with cholesterol, these cells become foam cells, which are major components of atherosclerotic lesions <ref name="lind"/>. Apolipoproteins, which facilitate the the removal of cholesterol from macrophages, can be degraded by cathepsin K at a pH of 6 <ref name="lind"/>. Advanced atherosclerotic cells have a low pH, optimal for cathepsin K activity <ref name="lut"/><ref name="lind"/>.
High expression of cathepsin K has been discovered in breast tumor cells, including those metastasized to bone tissue <ref name="little"/>. As cathepsin K is capable of extracellular collagen degradation, this protease may function in tumor cells as a means of bone tissue invasion <ref name="little"/>.


== Relevance ==
== Relevance ==


== Structural highlights ==
Cathepsin K inhibitors have been thought potential treatments for osteoporosis, as high collagenolytic activity by cathepsin K has been identified among patients with this condition <ref name="stoch"/>. However, it has been suggested that the inhibition of Cathespin K may not result in strengthened bone tissue <ref name="vaan"/>. Osteoclasts implement bone resorption in two sequential processes. First, acid is secreted onto the bone surface to demineralize the bone tissue <ref name="zao"/><ref name="stoch"/>. Second, the acid secretion and consequential decrease in pH results in the activation of proteases – including cathepsin k – which degrade the bone matrix <ref name="zao"/><ref name="stoch"/>. Since demineralization of bone is induced by acid secretion and can continue without cathepsin K, the inhibition of this protease may merely result in the accumulation of weakened bone tissue <ref name="vaan"/><ref name="zao"/><ref name="stoch"/>.


This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
As cathepsin K takes part in cartilage degradation by cleavage of type II collagen, the inhibition of this protease could be a treatment for rheumatoid arthritis <ref name="hou"/>. Articular bone and cartilage degradation, as seen in rheumatoid arthritis, is largely conducted by osteoclasts and synovial fibroblasts, which highly express cathepsin K in inflamed arthritic joint tissue <ref name="hou"/>.  


Cathepsin K inhibitors have also been considered for the treatment or prevention of atherosclerosis, as cathepsin K promotes the accumulation of cholesterol in macrophages, leading to foam cell production and atherosclerotic lesions <ref name="lind"/>.
Expression of cathepsin K has been identified in breast cancer tumor cells, as well as metastases embedded in bone tissue <ref name="little"/>. Since bone is a common site for tumor metastasis, the inhibition of cathepsin K in tumor cells may prevent or impede the development of malignant bone tumors <ref name="little"/>.
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>
==Content Donors==
Hamed Aldhahri, Casey Bartel, Stuart Harris, Luke Parry, Lauren Sharpe, and Allison Weinschreider contributed to the research of cathepsin K presented in the article.

Latest revision as of 09:50, 8 December 2019

Human Cathepsin K

Drag the structure with the mouse to rotate

References


Content Donors

Hamed Aldhahri, Casey Bartel, Stuart Harris, Luke Parry, Lauren Sharpe, and Allison Weinschreider contributed to the research of cathepsin K presented in the article.

Proteopedia Page Contributors and Editors (what is this?)

Lauren Sharpe, Alexander Berchansky, Michal Harel